Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 7004633756
ResearcherID: A-4264-2015

Activities

Collapse all

Employment (5)

University of Genoa: Genoa, Liguria, IT

2021-09-01 to present | Full Professor of Biochemistry (Dept of Experimental Medicine)
Employment
Source: Self-asserted source
Santina Bruzzone

University of Genoa: Genoa, Liguria, IT

2016-04-01 to 2021-08-31 | Associate Professor of Biochemistry (Department of Experimental Medicine)
Employment
Source: Self-asserted source
Santina Bruzzone

University of Genova: Genova, IT

2005-12-31 to 2016-03-31 | Assistant Professor of Biochemistry (Dept of Experimental Medicine)
Employment
Source: Self-asserted source
Santina Bruzzone

University of Genova: Genova, IT

2002-01-01 to 2005-12-30 | Post doctoral fellow (Dept of Experimental Medicine)
Employment
Source: Self-asserted source
Santina Bruzzone

University of Minnesota : Minneapolis, MN, US

2001-04-01 to 2001-12-21 | Post doctoral fellow (Dept of Pharmacology)
Employment
Source: Self-asserted source
Santina Bruzzone

Education and qualifications (2)

University of Milano: Milano, IT

1996-11-01 to 2000-12-20
Education
Source: Self-asserted source
Santina Bruzzone

University of Genova, Italy: Genova, IT

1991-10-01 to 1996-07-17 | Degree in Biology
Education
Source: Self-asserted source
Santina Bruzzone

Funding (19)

Genomic, proteomic and metabolomic characterization of hypoxia-dependent Hematopoietic Stem Cells to improve their harvesting and downstream applications

2023 to 2025 | Grant
Ministry of Education, Universities and Research (Rome, IT)
Source: Self-asserted source
Santina Bruzzone

NADIS - NAD+ International Scientist-Training Programme

2022 to 2026 | Grant
HORIZON EUROPE Marie Sklodowska-Curie Actions (Bruxelles, BE)
Source: Self-asserted source
Santina Bruzzone

Dissecting hypoxia-induced metabolism to advance ex vivo manipulation of Hematopoietic Stem Cells

2022 to 2024 | Grant
Compagnia di San Paolo (Turin, IT)
Source: Self-asserted source
Santina Bruzzone

Lead optimization of MKT-077 analogues as HSP70 allosteric inhibitors combined with F508del CFTR correctors: a multi-drug approach to contrast cystic fibrosis.

2021 to 2023 | Grant
Fondazione per la Ricerca sulla Fibrosi Cistica (Verona, IT)
Source: Self-asserted source
Santina Bruzzone

Role and regulation of inflammation in pediatric muscle dystrophy: new therapeutic perspective

2020 to 2022 | Grant
Compagnia di San Paolo (Torino, IT)
Source: Self-asserted source
Santina Bruzzone

Characterization of the hematopoietic niche under physiological and stress conditions by the use of microfluidic bioreactors and engineered red blood cells.

2019 to 2022 | Grant
Ministero dell’Istruzione, dell’Università e della Ricerca (Roma, IT)
Source: Self-asserted source
Santina Bruzzone

Optimization of SIRT6 inhibitors and PoC studies in a skin field cancerization model

2018 to 2022 | Grant
H2020 Marie Skłodowska-Curie Actions (Bruxelles, BE)
Source: Self-asserted source
Santina Bruzzone

SIRT6 inhibition as a therapeutic approach for treating multiple sclerosis.

2018 to 2019 | Grant
Fondazione Italiana Sclerosi Multipla (Genova, IT)
Source: Self-asserted source
Santina Bruzzone

Role of the intracellular adenine nucleotides cAMP, cADPR and ADPR in adipose tissue browning and inflammation

2018 to 2018 | Salary award
Deutscher Akademischer Austauschdienst (Berlin, DE)
Source: Self-asserted source
Santina Bruzzone

Role of P2X7 in myelination: therapeutic implications for treatment of the peripheral neurophaty Charcot-Marie-Tooth 1A

2013-05 to 2013-07 | Salary award
DAAD, German Academic Exchange Service (Berlin, DE)
Source: Self-asserted source
Santina Bruzzone

NAD biosynthesis and metabolism as new therapeutic target in cancer

2013 to 2014 | Grant
University of Genova (Genova, IT)
Source: Self-asserted source
Santina Bruzzone

Role of P2X7 in myelination: therapeutic implications for treatment of the peripheral neurophaty Charcot-Marie-Tooth 1A

2012 to 2014 | Grant
Fondazione Telethon (Roma, IT)
Source: Self-asserted source
Santina Bruzzone

Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure.

2011 to 2016 | Grant
FP7 (Bruxelles , BE)
Source: Self-asserted source
Santina Bruzzone

Preclinical evaluation of the NAMPT inhibitor FK866 for the treatment of autoimmunity and lymphoblastic leukemia

2011 to 2014 | Grant
MIUR: Italian Ministry of Instruction, University, Research (Roma, IT)
Source: Self-asserted source
Santina Bruzzone

Role of abscisic acid in the regulation of the glycemic homeostasis and in the pathogenesis of diabetes mellitus and metabolic syndrome

2011 to 2013 | Grant
University of Genova (Genova, IT)
Source: Self-asserted source
Santina Bruzzone

Role of NAD and NAD-dependent enzymes in lymphocytes activation: mechanisms and therapeutic implications for multiple sclerosis

2011 to 2011 | Grant
Fondazione CARIGE (Genova, IT)
Source: Self-asserted source
Santina Bruzzone

Role of P2X7 in myelination: therapeutic implications for treatment of the peripheral neurophaty Charcot-Marie-Tooth 1A

2010 to 2011 | Grant
University of Genova (Genova, IT)
Source: Self-asserted source
Santina Bruzzone

Novel adenylyc dinucleotides (P18 and P24) modulators of the purinergic receptor P2X7 and with anti-tumoral activity

2008 to 2010 | Grant
University of Genova (Genova, IT)
Source: Self-asserted source
Santina Bruzzone

Molecular and cellular interactions among second messengers in the regulation of intracellular calcium

2006 to 2007 | Grant
University of Genova (Genova, IT)
Source: Self-asserted source
Santina Bruzzone

Peer review (1 review for 1 publication/grant)

Review activity for Journal of medicinal chemistry. (1)
How many people are using ORCID?